Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis

Fernando Paganelli, José A. Cardillo, Alessandro R.J. Dare, Luiz A.S. Melo, David R. Lucena, Arnobio A. Silva, Anselmo G. Oliveira, Antonio C. Pizzolitto, Daniel Lavinsky, Mirian Skaf, Accio A. Souza-Filho, Ana L. Hfling-Lima, Quan Dong Nguyen, Baruch D. Kuppermann, Rocio Herrero-Vanrell, Rubens Belfort

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

Original languageEnglish (US)
Pages (from-to)955-965
Number of pages11
JournalExpert Opinion on Drug Delivery
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Drug Compounding
Anti-Inflammatory Agents
Pharmaceutical Preparations
Inflammation
Eye Infections
Topical Administration
Sclera
Endophthalmitis
Therapeutics
Patient Compliance
Anti-Infective Agents
Cataract
Permeability
Steroids

Keywords

  • Antibiotics
  • Antimicrobials
  • Cataract surgery
  • Endophthalmitis
  • Eye drops
  • Eye infections
  • Intraocular penetration
  • Ocular drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Controlled transscleral drug delivery formulations to the eye : Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. / Paganelli, Fernando; Cardillo, José A.; Dare, Alessandro R.J.; Melo, Luiz A.S.; Lucena, David R.; Silva, Arnobio A.; Oliveira, Anselmo G.; Pizzolitto, Antonio C.; Lavinsky, Daniel; Skaf, Mirian; Souza-Filho, Accio A.; Hfling-Lima, Ana L.; Nguyen, Quan Dong; Kuppermann, Baruch D.; Herrero-Vanrell, Rocio; Belfort, Rubens.

In: Expert Opinion on Drug Delivery, Vol. 7, No. 8, 01.08.2010, p. 955-965.

Research output: Contribution to journalReview article

Paganelli, F, Cardillo, JA, Dare, ARJ, Melo, LAS, Lucena, DR, Silva, AA, Oliveira, AG, Pizzolitto, AC, Lavinsky, D, Skaf, M, Souza-Filho, AA, Hfling-Lima, AL, Nguyen, QD, Kuppermann, BD, Herrero-Vanrell, R & Belfort, R 2010, 'Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis', Expert Opinion on Drug Delivery, vol. 7, no. 8, pp. 955-965. https://doi.org/10.1517/17425247.2010.498817
Paganelli, Fernando ; Cardillo, José A. ; Dare, Alessandro R.J. ; Melo, Luiz A.S. ; Lucena, David R. ; Silva, Arnobio A. ; Oliveira, Anselmo G. ; Pizzolitto, Antonio C. ; Lavinsky, Daniel ; Skaf, Mirian ; Souza-Filho, Accio A. ; Hfling-Lima, Ana L. ; Nguyen, Quan Dong ; Kuppermann, Baruch D. ; Herrero-Vanrell, Rocio ; Belfort, Rubens. / Controlled transscleral drug delivery formulations to the eye : Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. In: Expert Opinion on Drug Delivery. 2010 ; Vol. 7, No. 8. pp. 955-965.
@article{ff075c5837b941299ded7237145bad96,
title = "Controlled transscleral drug delivery formulations to the eye: Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis",
abstract = "Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.",
keywords = "Antibiotics, Antimicrobials, Cataract surgery, Endophthalmitis, Eye drops, Eye infections, Intraocular penetration, Ocular drug delivery",
author = "Fernando Paganelli and Cardillo, {Jos{\'e} A.} and Dare, {Alessandro R.J.} and Melo, {Luiz A.S.} and Lucena, {David R.} and Silva, {Arnobio A.} and Oliveira, {Anselmo G.} and Pizzolitto, {Antonio C.} and Daniel Lavinsky and Mirian Skaf and Souza-Filho, {Accio A.} and Hfling-Lima, {Ana L.} and Nguyen, {Quan Dong} and Kuppermann, {Baruch D.} and Rocio Herrero-Vanrell and Rubens Belfort",
year = "2010",
month = "8",
day = "1",
doi = "10.1517/17425247.2010.498817",
language = "English (US)",
volume = "7",
pages = "955--965",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Controlled transscleral drug delivery formulations to the eye

T2 - Establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis

AU - Paganelli, Fernando

AU - Cardillo, José A.

AU - Dare, Alessandro R.J.

AU - Melo, Luiz A.S.

AU - Lucena, David R.

AU - Silva, Arnobio A.

AU - Oliveira, Anselmo G.

AU - Pizzolitto, Antonio C.

AU - Lavinsky, Daniel

AU - Skaf, Mirian

AU - Souza-Filho, Accio A.

AU - Hfling-Lima, Ana L.

AU - Nguyen, Quan Dong

AU - Kuppermann, Baruch D.

AU - Herrero-Vanrell, Rocio

AU - Belfort, Rubens

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

AB - Importance of the field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting. Area covered in this review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis. What the reader will gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery. Take home message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.

KW - Antibiotics

KW - Antimicrobials

KW - Cataract surgery

KW - Endophthalmitis

KW - Eye drops

KW - Eye infections

KW - Intraocular penetration

KW - Ocular drug delivery

UR - http://www.scopus.com/inward/record.url?scp=77954876943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954876943&partnerID=8YFLogxK

U2 - 10.1517/17425247.2010.498817

DO - 10.1517/17425247.2010.498817

M3 - Review article

C2 - 20645672

AN - SCOPUS:77954876943

VL - 7

SP - 955

EP - 965

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -